FDA issues warning over Celebrex, Bextra ads

Share this article:
The FDA has issued a warning letter to Pfizer stating that television and print ads for its painkillers Celebrex and Bextra are misleading to consumers.
A total of five advertisements failed to disclose side effects and other risk information and made "unsubstantiated effectiveness claims," the letter posted on the FDA's Web site Wednesday said.
A company spokeswoman told Reuters the Celebrex ads cited in the letter were no longer running. The spokeswoman had no comment on the other materials including a Bextra patient brochure and a television infomercial.
Pfizer said in a Reuters report it would discuss its next steps with the FDA. The letter gives Pfizer until Jan. 26 to respond.
On Dec. 17, the National Institutes of Health halted a cancer trial using Celebrex after researchers discovered an increased risk of heart attack.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.